Novel functions of intracellular IL-1ra in human dermal fibroblasts: implications in the pathogenesis of fibrosis

J Invest Dermatol. 2006 Apr;126(4):756-65. doi: 10.1038/sj.jid.5700097.

Abstract

Intracellular IL-1 receptor antagonist (icIL-1ra) is reportedly involved in functions independent of blocking IL-1 receptor signaling. Fibroblasts derived from the involved skin of patients with systemic sclerosis (SSc) are predominantly of the myofibroblast phenotype, with higher levels of icIL-1ra compared to normal skin fibroblasts. We examined the effect of overexpression of icIL-1ra on the phenotype and function of normal fibroblasts with respect to the expression of alpha smooth muscle actin (alpha-SMA), a specific marker for myofibroblasts, and plasminogen activator inhibitor (PAI), a protein involved in fibrogenesis and expressed at higher levels in myofibroblasts, and the production of collagenase (matrix metalloproteinase-1 (MMP-1)), the major enzyme involved in the degradation of native collagen in the skin. Normal human foreskin fibroblasts overexpressing icIL-1ra showed higher levels of alpha-SMA and PAI and had lower levels of collagenase and MMP-1 mRNA induced by inflammatory cytokines. By contrast, levels of mRNA for tissue inhibitor of metalloproteinase-1 in the transfected cells were not different from the control cells. Pretreatment of the ic-IL-1ra-transfected cells with antisense oligonucleotide directed against the mRNA of icIL-1ra restored MMP-1 expression induced by stimulation with IL-1beta. Our data indicate novel functions for icIL-1ra, which might be relevant to the genesis of fibrotic diseases such as SSc.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Actins / metabolism
  • Dermis / cytology*
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism*
  • Fibrosis
  • Humans
  • Interleukin 1 Receptor Antagonist Protein
  • Matrix Metalloproteinase 1 / metabolism
  • Oligodeoxyribonucleotides, Antisense / pharmacology
  • Phenotype
  • Plasminogen Inactivators / genetics
  • Plasminogen Inactivators / metabolism
  • Scleroderma, Systemic / etiology*
  • Scleroderma, Systemic / metabolism
  • Scleroderma, Systemic / pathology
  • Sialoglycoproteins / antagonists & inhibitors
  • Sialoglycoproteins / genetics
  • Sialoglycoproteins / physiology*
  • Skin / pathology
  • Tissue Inhibitor of Metalloproteinase-1 / genetics
  • Tissue Inhibitor of Metalloproteinase-1 / metabolism
  • Transcriptional Activation
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Actins
  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Oligodeoxyribonucleotides, Antisense
  • Plasminogen Inactivators
  • Sialoglycoproteins
  • Tissue Inhibitor of Metalloproteinase-1
  • Tumor Necrosis Factor-alpha
  • Matrix Metalloproteinase 1